Managing the significant drug‐drug interaction between isavuconazole and tacrolimus in solid organ transplant recipients
Clinical Transplantation · 2024
DOI: 10.1111/ctr.15278 ↗At a glance
Leserbrief in Clinical Transplantation, 2024. Written by Jessica Hedvat and 4 co-authors. Institution: Department of Pharmacy, NewYork-Presbyterian Hospital, New York City, New York, USA. Major MEDLINE topics: Tacrolimus, Organ Transplantation, Nitriles, Pyridines. 5 references.
Abstract (original language)
Managing the significant drug-drug interaction between isavuconazole and tacrolimus in solid organ transplant recipientsWhile fungal infections are relatively uncommon in solid organ transplant (SOT) recipients, they are associated with significant morbidity and mortality.1 Further, either treatment or prophylaxis against fungal infections usually involves the use of azole antifungals.2 Isavuconazonium sulfate has become an attractive option for either prophylaxis or treatment of various mold species in high-risk patients after transplant due to its broad spectrum of activity, limited need for monitoring, and more tolerable side effect profile compared to posaconazole and voriconazole.According to the product labeling, isavuconazole is listed as a moderate inhibitor of cytochrome P450 3A4 and a mild inhibitor of P-glycoprotein and organic cation transporter 2, and caution is advised when using isavuconazole and tacrolimus concomitantly. 3 There are currently conflicting data on the degree of the interaction in SOT recipients and whether empiric tacrolimus dose adjustments are needed when isavuconazole is initiated.4,5 We conducted this F I G U R E 1 (A) Tacrolimus dose-corrected trough concentrations and (B) tacrolimus trough concentrations.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Pharmacy, NewYork-Presbyterian Hospital, New York City, New York, USA.
- Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York City, New York, USA.
ORCID profiles: Jessica Hedvat, Nicholas W Lange, Marcus R Pereira, David M Salerno
Cite
APA
Hedvat, J., Lange, N. W., Scheffert, J. L., Pereira, M. R., & Salerno, D. M. (2024). Managing the significant drug‐drug interaction between isavuconazole and tacrolimus in solid organ transplant recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.15278
Vancouver
Hedvat J, Lange NW, Scheffert JL, Pereira MR, Salerno DM. Managing the significant drug‐drug interaction between isavuconazole and tacrolimus in solid organ transplant recipients. Clinical Transplantation. 2024. doi:10.1111/ctr.15278
BibTeX
@article{Hedvat2024,
author = {Hedvat, Jessica and Lange, Nicholas W and Scheffert, Jenna L and Pereira, Marcus R and Salerno, David M},
title = {Managing the significant drug‐drug interaction between isavuconazole and tacrolimus in solid organ transplant recipients},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.15278}
}
EUVIMED